$23.28
-0.09 (-0.39%)
Myriad Genetics, Inc. (NASDAQ:MYGN)
CAPS Rating:
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.